Federal Drug and Alcohol Program evaluation finds reach and alignment but data gaps limit proof of impact

What the report is and what it covers

The Department of Health, Disability and Ageing commissioned KPMG and the University of Queensland to evaluate the Drug and Alcohol Program (DAP). The final evaluation report (dated 31 October 2025, published 18 December 2025) examines DAP administration and impact between 1 July 2021 and 31 March 2025. The evaluation focused on six DAP sub‑streams including prevention programs, national prevention projects, fetal alcohol spectrum disorder (FASD) work, withdrawal management and rehabilitation services, AOD treatment in areas of identified need, and Primary Health Network (PHN)‑commissioned services.

How the evaluation was done

The evaluators used mixed methods: a rapid literature review (246 sources), an organisational survey (107 responses — 76 provider and 31 PHN responses representing 22 PHNs), 46 discovery consultations with policy and sector stakeholders, 28 provider consultations, analysis of 1,379 program documents and exploration of available population datasets. The report explicitly notes quantitative and data‑quality constraints that limited some analyses.

Key findings — implementation and appropriateness

• Implementation and alignment: The report finds the DAP funds services that are intended to meet its objectives, but it identifies opportunities to improve implementation planning and program guidance. In particular, it recommends updating Grant Opportunity Guidelines so they explicitly align with national AOD strategy and clarifying implementation plans and performance monitoring (sufficient evidence).
• Coordination and system leadership: The evaluation records a sector desire for stronger Australian Government leadership and coordination across funders (Commonwealth, states/territories, PHNs and NIAA) and for mechanisms that incorporate provider and lived‑experience voices (sufficient evidence).
• Workforce and peer roles: The report highlights workforce pressures (recruitment and retention) and recommends stronger policy positions and guidance on embedding and supporting peer/lived‑experience workforces.

Key findings — impact and efficiency

• Access and local benefit: Stakeholders consistently reported that DAP funding improves service access, contributes to provider viability and supports local prevention activity. Some flagship program evaluations showed increased reach and awareness for prevention work (weak evidence for broad impact).
• Data and attribution limits: The evaluation found population‑level datasets provided context but could not be used to attribute changes to DAP activity. Weaknesses in consistency, completeness and linkage of program data constrained rigorous impact and cost‑effectiveness analysis (weak to some evidence).
• Efficiency opportunities: The report recommends streamlining how DAP funding streams are organised, harmonising reporting requirements and improving cost recording to better assess value for money (some evidence).

What the report does not do

The evaluation makes recommendations and identifies sustainability considerations but does not itself implement policy or change funding rules. It does not establish that the department or government has accepted or will adopt the recommendations.

What this could mean in practice

If adopted, the report’s recommendations would primarily affect how the department frames grant guidance, monitors performance and works with other funders. For providers, clearer KPIs and harmonised reporting could change contract expectations and data collection practices. Workforce guidance and greater support for peer roles could shift staffing priorities and approaches to consumer engagement. These are practical consequences that follow from the report’s confirmed recommendations; they do not presuppose any government decision to act.

What to watch next (as of 19 Sep 2026)

• Whether the department updates DAP Grant Opportunity Guidelines and publishes a refreshed DAP workplan tied to the National Drug Strategy.
• Any department action to harmonise reporting KPIs for DAP grants and to commission data linkage or a revised monitoring and evaluation framework.
• Formal government responses or funding decisions that accept, adapt or reject the evaluation recommendations.

Bottom line

The evaluation concludes the DAP is aligned to its objectives and supports access to services, but persistent data and attribution limitations mean the program’s impact on population harms cannot be robustly quantified from existing information. The report’s recommendations are focused and actionable: clearer guidance, stronger coordination, workforce support and a fit‑for‑purpose monitoring framework.